Phospho-Specific Flow Cytometry Reveals Signaling Heterogeneity in T-Cell Acute Lymphoblastic Leukemia Cell Lines

Omar Perbellini 1, Chiara Cavallini 2, Roberto Chignola 3, Marilisa Galasso 4 and Maria T. Scupoli 2,4,*

Abstract: Several signaling pathways are aberrantly activated in T-ALL due to genetic alterations of their components and in response to external microenvironmental cues. To functionally characterize elements of the signaling network in T-ALL, here we analyzed ten signaling proteins that are frequently altered in T-ALL—namely Akt, Erk1/2, JNK, Lck, NF-κB p65, p38, STAT3, STAT5, ZAP70, Rb—in Jurkat, CEM and MOLT4 cell lines, using phospho-specific flow cytometry. Phosphorylation statuses of signaling proteins were measured in the basal condition or under modulation with H2O2, PMA, CXCL12 or IL7. Signaling profiles are characterized by a high variability across the analyzed T-ALL cell lines. Hierarchical clustering analysis documents that higher intrinsic phosphorylation of Erk1/2, Lck, ZAP70, and Akt, together with ZAP70 phosphorylation induced by H2O2, identifies Jurkat cells. In contrast, CEM are characterized by higher intrinsic phosphorylation of JNK and Rb and higher responsiveness of Akt to external stimuli. MOLT4 cells are characterized by higher basal STAT3 phosphorylation. These data document that phospho-specific flow cytometry reveals a high variability in intrinsic as well as modulated signaling networks across different T-ALL cell lines. Characterizing signaling network profiles across individual leukemia could provide the basis to identify molecular targets for personalized T-ALL therapy.

Keywords: cell signaling; leukemia; flow cytometry

1. Introduction

T-cell acute lymphoblastic leukemia (T-ALL) is a malignancy of immature T cells at defined stages of intrathymic T-cell differentiation [1]. T-ALL accounts for about 15% of pediatric and 25% of adult ALL cases [2,3]. Over the past last decades, survival rates of patients with T-ALL have remarkably improved thanks to advances in combined chemotherapy protocols [4]. However, primary resistance to treatment and relapse are observed in a significant number of patients [5]. The poor outcome of T-ALL patients has been related to disease complexity, where genetic and microenvironmental factors interact in supporting leukemia progression and resistance [6]. Therefore, for a comprehensive classification of the disease and for developing personalized therapeutic strategies, it is challenging to gain an integrated, overall picture of changes of the entire leukemia cell signaling.

Immunophenotyping allows the classification of T-ALL in different subgroups based on the corresponding stage of T-cell ontogenesis [7]. The prognostic value of different immunophenotypic groups differs between the studies, also in the case of early T-cell precursor ALL (ETP-ALL), which is a very unique subgroup in T-ALL [8–10]. At the
molecular level, T-ALL is a heterogenous disease characterized by a wide spectrum of genetic lesions [11] as well as by altered interpretation of external cues deriving from the microenvironment [6]. Both cell-intrinsic defects and microenvironmental stimuli converge on the activation of regulatory signaling pathways involved in processes enhancing the capacity of self-renewal, overturning the control of cell proliferation, blocking differentiation, and promoting resistance to apoptosis. Signaling pathways that are aberrantly activated in T-ALL include phosphatidylinositol-3OH-kinase (PI3K)/Akt, mitogen-activated protein kinases (MAPKs), and Janus kinases/signal transducer activator of transcription Jak/STAT [12,13]. These signaling pathways can be activated due to genetic alterations of their components as well as in response to external microenvironmental cues. Amongst cell-extrinsic modulators, the chemokine CXCL12 and interleukin 7 (IL7) play a key role in promoting tumor growth [14–18].

CXCL12 is a homeostatic chemokine secreted by stromal cells, fibroblasts and epithelial cells within tissue microenvironments, including lymph nodes and bone marrow (BM) [19–21]. CXCL12 binds the CXC-chemokine receptors 4 (CXCR4) and 7 (CXCR7) [22]. Interaction of CXCL12 with CXCR4 triggers complex signaling pathways, which include PI3K/Akt, the MAPK extracellular signal-regulated kinase (Erk)1/2 and p38, and Jak/STAT, regulating intracellular calcium flux, chemotaxis, transcription and cell survival [23–25]. Evidence indicates that the CXCL12/CXCR4 signaling axis plays a role in cancer biology, in solid tumors as well as in hematological malignancies such as T-ALL, where the CXCL12/CXCR4 signaling regulates the maintenance and progression of leukemia [18,26–29]. The CXCL12/CXCR7 binding induces intracellular signaling pathways, such as PI3K/Akt, MAPK, Jak/STAT3 [22]. However, the role of CXCR7 in cancer progression is controversial, as some reports suggest pro-metastatic responses, while others indicate inhibition of metastasis [19]. In T-ALL, CXCR7 has been suggested to contribute to leukemic-cell migration, potentiating the CXCL12/CXCR4 axis [30].

IL7 is a cytokine produced by stromal cells in the BM, thymus and other tissues. The IL7 receptor (IL7R) is expressed mainly by lymphoid cells [31]. The IL7/IL7R interaction is required for normal T-cell development and homeostasis of mature T-cells [31]. IL7/IL7R-mediated binding activates three main signaling pathways: Jak/STAT, MAPK/Erk and PI3K/Akt/mammalian target of rapamycin (mTOR) [32] in both T-ALL and healthy T-cells [33,34]. However, while PI3K/Akt/mTOR signaling mediated by IL7 promotes proliferation and survival of T-ALL cells by inducing downregulation of p27kip1 and upregulation of Bcl-2 [35,36], in healthy T cells PI3K signaling activation by IL7 induces cell cycle progression without influencing cell survival [37,38].

To gain overall picture of intrinsic and extrinsic signaling in T-ALL cells, in this study we investigated signaling pathways in three T-ALL cell lines, namely CEM, MOLT4 and Jurkat, using phospho-specific flow cytometry that simultaneously determines protein expression and protein post-translational modifications (i.e., phosphorylation) at a single cell level [39–42]. Our results show that single-cell signaling profiles measured by phospho-specific flow cytometry allow us to reveal heterogeneous signaling profiles in the analyzed T-ALL cell lines.

2. Materials and Methods

2.1. Cell Samples

The cryopreserved T-ALL cell lines CEM, MOLT4 and Jurkat (American Type Culture Collection, ATCC) were cultured in medium RPMI-1640 (GIBCO; Thermo Fisher Scientific, Waltham, MA) with 10% fetal bovine serum (FBS, GIBCO) at 37 °C in a humidified atmosphere containing 5% CO2. Peripheral mononuclear cells (PBMC) were obtained from heparin-anticoagulated leukocyte concentrate samples collected as from healthy donors (HDs) at the Transfusion Medicine Unit, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy. In accordance with the Declaration of Helsinki, all blood donors provided written informed consent for the anonymous collection and use of their...
leukocyte concentrate samples—as byproduct of the manufacturing of blood donation—for research purposes.

PBMCs were isolated by Ficoll-hypaque centrifugation (Lymphoprep; Nicomed, Oslo, Norway) and cryopreserved in liquid nitrogen. Thawing of T-ALL cell lines and PBMC from HDs was performed at 37 °C and transferred in a 1:1 solution of RPMI-1640 complete medium and heat inactivated FBS. Cells were pelleted at 400 g for 5 min and resuspended in prewarmed (37 °C) complete RPMI-1640 medium. Before use, viability of the cells was over 90%, as assessed by flow cytometry analysis after staining with 7-amino-actinomycin D (7-AAD; BD Biosciences, BD Biosciences, San Jose, CA, USA).

2.2. Immunophenotype Characterization

Immunophenotype characterization of CEM, MOLT4, and Jurkat cell lines was performed as previously described [43]. T-ALL cell lines were classified according to their maturation stage using the criteria defined by the European Group for Immunological Characterization of Leukemias (EGIL) [7]. Cell surface expression of CD127 and CD184 was detected by staining cells with fluorochrome-conjugated antibodies in the dark at room temperature for 15 min. The complete list of antibodies used is reported in Supplementary Table S1. Autofluorescence controls were used to set background signals. Samples were then washed and analyzed on a FACSCanto cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Approximately 10,000 gated events were acquired for each sample.

2.3. Cell Treatments

Before treatments, cell lines and PBMC from HDs were stained with LIVE/DEAD Fixable Near-IR stain (Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Briefly, cells were collected, washed, counted, resuspended in PBS at 1 × 10⁶/mL and stained with the reactive dye in the dark at room temperature for 30 min. After two washes with PBS, cell lines and PBMC were resuspended in RPMI-1640 with 10% fetal bovine serum at 2 × 10⁶/mL and 4 × 10⁶/mL, respectively; divided in 5 tubes and rested at 37 °C in a humidified atmosphere containing 5% CO₂ for 1 h. Each tube was then treated with a different modulator for 15 min (Supplementary Table S2) for phospho-specific flow cytometry. Unmodulated cells were used as control.

2.4. Phospho-Specific Flow Cytometry

Phospho-specific flow cytometry was performed as previously described [40]. Briefly, after 15 min of treatment, cells were fixed with pre-warmed Fix Buffer I (Becton Dickinson) at 37 °C for 10 min and permeabilized with ice-cold 50% methanol for 30 min on ice. Permeabilized cells were washed with PBS containing 0.1% bovine serum albumin and stained with fluorochrome-conjugated antibodies in the dark at room temperature for 40 min. The complete list of antibodies used, and the staining panels are reported in Supplementary Table S3 and Supplementary Table S4, respectively. Isotype controls were used to set background signals. Three independent experiments were performed for each cell line and for HD T cells. Approximately 10,000 gated events were acquired for each sample on a FACSCanto cytometer (Becton Dickinson).

2.5. Flow Cytometry Data Analysis

Flow cytometry data were processed, analyzed, and graphed using FlowJo software (v10.8; TreeStar, Ashland, OR, USA). Dead cells, debris and doublets were excluded based on forward-scatter, side-scatter, and LIVE/DEAD signals. All analyses were performed on gated T cells, identified as CD45/CD3 co-expressing cells in HD samples and as cCD3 or CD7 positive in T-ALL cell lines. Median fluorescence intensity (MFI) was normalized with respect to MFI of isotype control (RMFI) and, when indicated, transformed into log₂ Basal phosphorylation statuses of signaling proteins were considered activated when RMFI >1. The response of cells to treatments was calculated as log₂Fold change [log₂(RMFI modulated/RMFI unmodulated)], as previously described [40]. A log₂ value equal to
0 corresponds to ‘no change’ with respect to the unstimulated. The response to external modulators was considered positive when log₂Fold change > 0. We used the term “node” to refer to a proteomic readout in the presence or absence of a specific modulator. For example, the response to CXCL12 modulation can be measured using pErk1/2 as a readout. That node is designated “CXCL12-pErk1/2” [40].

2.6. Statistical Analysis

The unsupervised hierarchical cluster analysis (HCA) was performed using webtool ClustVis (v. 2.0, https://biit.cs.ut.ee/clustvis/; accessed on 21 September 2021) [44], calculating the Euclidean distances as the distance metric and the complete linkage as linkage method of analysis. Comparison of phosphorylation levels among T-ALL cell lines and healthy donor (HD) T cells were performed using the Kruskal–Wallis test and each p value was corrected for multiple comparisons using the Dunn’s test. Differences were considered statistically significant when p ≤ 0. Graphing and statistical analyses were performed using GraphPad Prism software (v. 7.03, GraphPad Software Inc., San Diego, CA, USA; accessed on 16 December 2021).

3. Results

3.1. Study Design

The phosphorylation levels of ten signaling proteins that are frequently altered in T-ALL (namely Akt, MAPK Erk1/2, c-Jun NH2-terminal protein kinase (JNK), lymphocyte-specific protein tyrosine kinase (Lck), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) p65, p38, STAT3, STAT5, zeta-chain-associated protein kinase 70 (ZAP70), and retinoblastoma protein (Rb)) were analyzed at the single-cell level in the T-ALL cell lines CEM, MOLT4, and Jurkat, using phospho-specific flow cytometry (Figure 1). Based on EGIL classification criteria [7], the T-ALL cell-lines were classified into categories corresponding to three differentiation stages, i.e., CEM corresponds to the T-II (pre-T) stage, MOLT4 to the T-III (cortical) stage, and Jurkat to the T-IV (mature) stage (Table 1). Phosphorylation statuses of signaling proteins were measured in the basal condition (i.e., unmodulated) or under modulation with H₂O₂, phorbol 12-myristate 13-acetate (PMA), CXCL12, or IL7.

Figure 1. Signaling pathways analyzed in the study. The analyzed phosphoproteins are highlighted in bold.
Table 1. T-ALL cell lines according to the EGIL classification.

| T-ALL Cell Lines | EGIL Classification | Markers |
|------------------|---------------------|---------|
|                  | CD2+/cCD3+          | CD2 and/or CD5 and/or CD8 | CD1a | mCD3 |
| Pro-T (T I)      | Neg                 | Neg | Neg | Neg |
| Pre-T (T II)     | Pos                 | Neg | Neg | Neg |
| Cortical T (T III) | Pos             | Pos | Neg | Neg |
| Mature T (T IV)  | Pos                 | Neg | Pos | Pos |

cCD3: cytoplasmic CD3; mCD3: membrane CD3; Neg: negative; Pos: positive.

3.2. Phosphorylation Profiles in the Basal, \( \text{H}_2\text{O}_2 \), and PMA-Modulated Conditions

The basal phosphorylation statuses of signaling proteins were highly heterogeneous among cell lines (σ² across the phosphoproteins was 2.7 for CEM, 6.0 for MOLT4, 20.7 for Jurkat; Figure 2A,B). All T-ALL cell lines showed basal phosphorylation (RMFI > 1.5) of Erk1/2, Lck, NF-κB p65, STAT3, and ZAP70\(^{Y319}\), with higher levels of Erk1/2, Lck, and ZAP70\(^{Y319}\) in Jurkat cells. JNK was phosphorylated in CEM and Jurkat cells. Rb was constitutively phosphorylated in CEM and MOLT4. Basal phosphorylation of Akt was detected in CEM and Jurkat cells, with higher levels in Jurkat. ZAP70\(^{Y292}\) was constitutively phosphorylated in Jurkat cells. Pp38 and pSTAT5 levels were undetectable in all the analyzed T-ALL cell populations (Figure 2A,B). Overall, the levels of phosphorylation—expressed as the sum of phosphoprotein RMFI—were higher in Jurkat than in CEM and MOLT4 (the sum ofRMFI was 33.12 for CEM; 30.54 for MOLT4; and 56.88 for Jurkat).

Then, we investigated the responsiveness of T-ALL cell lines to \( \text{H}_2\text{O}_2 \), which reversibly inhibits tyrosine phosphatases thereby shifting the equilibrium of phosphorylation reaction in favor of kinase activation [45]. Responses to \( \text{H}_2\text{O}_2 \) were measured as the log\(_2\) Fold change in phosphorylation between \( \text{H}_2\text{O}_2 \)-modulated and unmodulated conditions. As shown in Figure 2C,D, \( \text{H}_2\text{O}_2 \) perturbed signaling profiles in all the analyzed leukemic cell populations. Specifically, \( \text{H}_2\text{O}_2 \) induced increased phosphorylation of STAT3 in all T-ALL cell lines, with a higher response of CEM compared with MOLT4 and Jurkat. Moreover, \( \text{H}_2\text{O}_2 \) induced a clear-cut increase of pAkt in CEM and MOLT4; of pErk1/2 in CEM and Jurkat cells; of NF-κB p65 in MOLT4 cells; of pZAP70\(^{Y319}\) and pZAP70\(^{Y292}\) in Jurkat cells. Overall, the phosphorylation responses to \( \text{H}_2\text{O}_2 \)—expressed as the sum of phosphoprotein responses—were higher in Jurkat cells and lower in CEM and MOLT4 (the sum of log\(_2\) Fold change in phosphorylation between \( \text{H}_2\text{O}_2 \)-modulated and unmodulated conditions was 1.86 for CEM; 3.98 for MOLT4; 5.89 for Jurkat).

Next, we stimulated T-ALL cell lines with PMA, which activates T cells through protein kinase C (PKC) [46]. As shown in Figure 2E,F, PMA induced a clear-cut increase of pSTAT3 in all T-ALL cell lines, with higher phosphorylation levels in CEM cells. Moreover, PMA induced augmented phosphorylation of Erk1/2 in CEM and Jurkat, and JNK in MOLT4.

Taken together, these data reveal high signaling variability across T-ALL cell lines with distinct phosphorylation profiles for each cell population and specific signaling sensitivity to phosphatase inhibition and to PKC activation.
3.3. Phosphorylation Profiles Following Modulation with CXCL12 or IL7

We examined the responses of phosphoproteins to some physiological stimuli relevant for T-ALL pathophysiology, i.e., CXCL12 and IL7, in T-ALL cell lines. All T-cell populations expressed the CXCL12 receptor CXCR4 (CD184), with T-ALL cell lines showing higher levels than HD T cells, used as control (Supplementary Figure S1A). Moreover, all T-ALL populations expressed very low levels of IL7Rα chain (CD127) (Supplementary Figure S1B). Responsiveness of T-ALL cell lines to external stimuli was measured as the log2Fold change in phosphorylation between modulated and unmodulated conditions (Figure 3). CXCL12 evoked a clear-cut increase of pAkt in CEM and MOLT4 and of pJNK in MOLT4 (Figure 3A,B). Engagement of IL7R with IL7 induced augmentation of pAkt in MOLT4 cells (Figure 3C,D). In contrast, STAT5 was unresponsive to IL7 in T-ALL cell lines, but not in HD T cells used as control (Figure 3C,D).
3.4. Signaling Profiles Separate T-ALL Cell Lines in Distinct Clusters

Basal phosphorylation statuses of signaling proteins—measured as log_2 RMFI—and responses to external stimuli—measured by the log_2 Fold change in phosphorylation between modulated and unmodulated conditions—were subjected to unsupervised hierarchical clustering analysis (HCA) within the three T-ALL cell populations. Unsupervised HCA of all the analyzed nodes (n = 55) identified CEM/MOLT4 cells and Jurkat as separate clusters (Supplementary Figure S2). To reduce the number of nodes that can discriminate T-ALL cell populations, next we performed an unsupervised HCA on selected nodes showing the greatest variation across samples (σ^2 of log_2 values > 0.5, n = 12). Remarkably, this clustering preserved the classification obtained analyzing all nodes and allowed us to identify significant nodes characterizing the different T-ALL cell lines (Figure 4). Specifically, Jurkat cells showed higher phosphorylation of basal-pErk1/2, basal-pLck, basal-pAkt, basal- and H_2O_2-induced pZAP70 nodes. CEM cells were characterized by increased basal pJNK and pRb, and Akt induced by CXCL12 and H_2O_2. MOLT4 cells exhibited higher STAT3 phosphorylation in the basal condition (Figure 4). These nodes were particularly important for T-cell classification since the clustering of T-ALL cell lines was lost if they were excluded from analysis (Supplementary Figure S3).
Figure 4. Unsupervised hierarchical clustering analysis on selected nodes. Unsupervised hierarchical clustering analysis of nodes showing higher variation ($\sigma^2$ of log$_2$ values > 0.5; $n = 12$) across samples within the T-ALL cell lines CEM, MOLT4, and Jurkat. Data are representative of three independent experiments.

Results from independent experiments showed an overall consistency of basal and induced phosphorylation measurements among experiments. Interestingly, comparison of these data across T-ALL and HD T cells showed that Jurkat significantly contrasted HD T cells by high levels of basal-pAkt, basal-pERK1/2, basal-pZAP70 Y319, and basal-pZAP70 Y292 (Figure 5A). Moreover, H$_2$O$_2$-induced pZAP70 Y292 was significantly higher in Jurkat when compared with CEM (Figure 5B). Compared with normal T cells, pRb in the basal condition and CXCL12-induced pAkt were significantly higher in CEM (Figure 5). In addition, pAkt induced by H$_2$O$_2$ was significantly higher in CEM when compared with Jurkat cells (Figure 5B).
while pSTAT3 increases in all cell lines, with a higher response in CEM cells that in contrast with a higher activation of Erk1/2, Lck, and ZAP70.

Indeed, previous studies have shown that signaling readouts in response to external modulators, rather than the basal levels of protein phosphorylation alone, are of clinical relevance in leukemia [40,41,47]. Besides the physiologic modulators CXCL12 and IL7, we used PMA to induce T-cell activation and H2O2 to inhibit protein tyrosine phosphatases (PTPs), thus enabling amplification of signaling events. Indeed, previous studies have shown that exposing cancer cells to potentiating inputs, such as H2O2, could allow us to discern cancer network profiles that correlate with disease outcome [41,48,49].

Our study shows that: (i) signaling profiles measured using phosphospecific flow cytometry are characterized by a high variability across the analyzed T-ALL cell lines; (ii) each cell line exhibits distinct intrinsic phosphorylation profiles and specific signaling sensitivity to external stimuli; and (iii) hierarchical analysis of signaling properties allows us to group T-ALL cell lines in two separate clusters.

Analysis of the phosphorylation status of signaling proteins in the unstimulated condition—which captures intrinsic signaling alterations—documents constitutive phosphorylation of pErk1/2, pNF-kB p65, pLck, ZAP70Y319, and pSTAT3 in all T-ALL cell lines, with a higher activation of Erk1/2, Lck, and ZAP70Y319 in Jurkat and higher levels of basal pSTAT3 in MOLT4 cells. Interestingly, in the presence of tyrosine-phosphatase inhibition as well as following PMA treatment, pErk1/2 further increases in CEM and Jurkat cells while pSTAT3 increases in all cell lines, with a higher response in CEM cells that in contrast...
Cells 2022, 11, 2072

exhibit low pSTAT3 in the basal condition. Moreover, inhibition of tyrosine phosphatase by 
$H_2O_2$ induces augmentation of pNF-$\kappa$B p65 in MOLT4.

Erks are members of the MAPK family that play an important role in both regulation of 
T-cell receptor (TCR) signaling [50] and functional responses [51] in T cells. The MAPK/Erk 
signaling pathway is frequently aberrantly activated in T-ALL, as a result of IL7R$\alpha$, JAK1, 
KRAS, NRAS, BRAF mutations [52,53]. Accordingly, the constitutive activation of Erk1/2 in 
T-ALL cell lines can account for mutations of KRAS in CEM; NRAS in MOLT4, and 
BRAF in Jurkat [54]. The MAPK/Erk signaling pathway is central in T-ALL and it has 
been recently shown to drive steroid resistance by phosphorylation and inactivation of 
the pro-apoptotic BH3-only protein BIM [12]. Remarkably, MEK inhibitors abolishes 
the inactivating phosphorylation of BIM and resensitizes steroid-resistant T-ALL cells in 
preclinical models [12].

NF-$\kappa$B family transcription factors are a common downstream target for inducible 
transcription mediated by many different cell-surface receptors, especially those receptors 
involved in inflammation and adaptive immunity [55]. In T cells, NF-$\kappa$B can be activated 
by a variety of immune signals and is involved in early thymocyte development and in 
antigen-dependent T-cell selection [56,57]. Although mutations in NF-$\kappa$B signaling genes 
are rare in T-ALL, consistently with our data, constitutive activation of the pathway is often 
observed in T-ALL [58,59]. NF-$\kappa$B signaling can be activated by several pathways, including 
PI3K/Akt and NOTCH1 [13]. The PI3K/Akt signaling pathway is frequently constitutively 
activated in T-ALL, mainly because of the inactivation of phosphatase and tensin homolog 
(PTEN), a phosphatase acting as negative regulator of the PI3K/Akt pathway [60,61]. 
Moreover, activating mutations in NOTCH1 have been identified in over 60% of T-ALL 
cases [62]. Consistently, PTEN inactivating mutations as well as NOTCH1 mutations have 
been documented in all the T-ALL cell lines analyzed in this study [54].

T-ALL cell lines also exhibit the concurrent phosphorylation of Lck and ZAP70$^{Y319}$, 
with higher phosphorylation levels observed in Jurkat cells. Interestingly, inhibition of 
tyrosine phosphatases further increases pZAP70$^{Y319}$ in Jurkat. Lck is a central kinase in 
T-cell precursors for the transition of CD4/CD8 double negative to double positive thymocytes and proliferation of early T-cell precursors [63]. Moreover, mice transgenic for 
active Lck develop thymic tumors, thus suggesting that Lck plays an important role in the 
pathogenesis of T-ALL [64]. The Lck and ZAP70 tyrosine kinases are crucial for initiating 
TCR signaling because TCR has no intrinsic enzymatic activity. Upon TCR stimulation, Lck 
phosphorylates the TCR, thus leading to the recruitment, phosphorylation, and activation 
of ZAP70 [65]. Moreover, the binding of the Lck SH2 domain to pZap70$^{Y319}$ may sustain 
Lck localization and the catalytic activities of both kinases, thereby providing positive feedback [66]. Therefore, our data suggest that the analyzed T-ALL cell lines show constitutive 
activation of phosphoproteins on the pre-TCR/TCR pathway, with higher activation levels 
detected in the more mature T-ALL cell line Jurkat. Interestingly, Jurkat cells also shows 
the constitutive phosphorylation of Zap70$^{Y292}$, which is increased following treatment with 
$H_2O_2$. The Y292 residue of Zap70 is known to mediate inactivation of the TCR signaling 
[67]. Taken together, these data are consistent with previous studies evidencing the 
crucial role of the preTCR complex signaling in supporting T-ALL leukemogenesis [68,69].

In contrast to the phosphorylation pattern described for Erk1/2, Lck, and ZAP-70$^{Y319}$ 
showing a higher intrinsic phosphorylation in Jurkat cells, we document a higher phospho-
rilation of STAT3 in MOLT4. The constitutive phosphorylation of STAT3 in all the T-ALL 
cell lines analyzed is consistent with previous studies showing high levels of pSTAT3 in T- 
ALL [70]. The apparent discordance with recent data from Bonaccorso et al. demonstrating 
no constitutive STAT3 phosphorylation in CEM and Jurkat cells [71] could be explained by 
the different STAT3 phospo-sites analyzed in the two studies (i.e., Y705 in the Bonaccorso’s 
analysis and S727 in our study). Remarkably, our data are coherent with the crucial role of 
persistently activated STAT3 in increasing tumor cell proliferation, survival and invasion 
while suppressing anti-tumor immunity [72].
Rb is constitutively phosphorylated in CEM and MOLT4, with CEM showing the highest levels of pRb. The tumor suppressor Rb is a negative regulator of cell cycle and Rb inactivation by deletion or hyperphosphorylation has been shown to induce cell-cycle progression in various cancers [73]. Hyperphosphorylation of Rb we document in T-ALL cell lines is in accordance with previous results demonstrating that Rb is hyperphosphorylated in most T-ALL primary samples [74] and supports the idea that deregulation of the cell cycle pathway in T-ALL is central in the pathogenesis of this disease.

Akt and JNK are constitutively phosphorylated in CEM and Jurkat cells, with Jurkat showing the higher intrinsic Akt phosphorylation. Moreover, in the presence of tyrosine phosphatase inhibition, pAkt levels are increased in CEM and MOLT4. The PI3K/Akt signaling pathway is frequently constitutively activated in T-ALL, mainly due to PTEN inactivating mutations [60,61], which is coherent with PTEN mutations documented in the analyzed T-ALL cell lines [54]. In normal T cells, the PI3K/Akt signaling pathway is a common effector cascade downstream of NOTCH, IL7, and pre-TCR signaling promoting survival and development of early T-cell precursors [75]. In T-ALL, the PI3K/Akt pathway is commonly activated generating anti-apoptotic and proliferative signals [60,61,76] and, accordingly, this signaling pathway has been explored as a novel therapeutic target in T-ALL [77]. PI3K inhibitors have shown some promising effects in T-ALL preclinical models [78]. Moreover, the Akt inhibitor triciribine induces cell cycle arrest and apoptosis and synergizes with vincristine in T-ALL cell line [79].

JNK, a member of MAPK superfamily, plays an oncogenic role in several cancers, especially in malignant lymphocytes [80–82]. Although the role of JNK activity in T-ALL remains largely unknown, we have previously shown that JNK activation is required for upregulating interleukin 8 expression induced by CXCL12 in primary T-ALL cells [18]. Moreover, inhibition of JNK activity has been shown to lead to cell cycle arrest and apoptosis [83,84]. Our data showing hyperphosphorylation of JNK in T-ALL cell lines suggests a role for JNK in sustaining leukemia.

Basal pSTAT5 and pp38 are both undetectable in the studied T-ALL cell lines, also in the presence of tyrosine-phosphatase inhibition and following treatment with PMA, CXCL12, or IL7.

All the analyzed T-ALL cell lines are unresponsive to IL7, probably due to the very low levels of CD127 expressed on the cell surface of these cells. Our data are in accordance with results from Bonaccorso et al., showing that basal STAT5 activation was low and nonresponsive to IL7 in PTEN-mutated T-ALL [71].

CXCL12 stimulation evokes a clear-cut increase of pAkt in CEM and MOLT4, and pJNK in MOLT4. Interestingly, Akt in CEM and MOLT4, and JNK in MOLT4 show low intrinsic phosphorylation levels. In contrast, Akt in Jurkat and JNK in CEM and Jurkat are highly phosphorylated in the basal condition. This phosphorylation pattern suggests that CXCL12 evokes Akt and JNK phosphorylation responses when these phosphoproteins are intrinsically inactive, whereas it is unable to further induce phosphorylation of Akt and JNK when they display high intrinsic activation status.

Hierarchical clustering analysis documents that higher intrinsic phosphorylation of Erk1/2, Lck, ZAP70, and Akt, together with ZAP70 phosphorylation in the presence of tyrosine-phosphatase inhibition, identifies Jurkat. Moreover, Jurkat cells exhibit higher phosphorylation levels of these nodes compared with normal T cells. In contrast, CEM are characterized by higher intrinsic phosphorylation of JNK and Rb and higher responsiveness of Akt to external stimuli, which are significantly higher in comparison with normal T cells. MOLT4 cells are characterized by higher STAT3 phosphorylation in the basal condition.

Our study originally shows that phosphospecific flow cytometry allows us to capture signaling network variability across different T-ALL cell lines. Although the use of cell lines does not allow us to relate signaling properties with disease characteristics, the ability to detect signaling heterogeneity among T-ALL cell lines—which can reflect biological heterogeneity of primary cells from which they derive—provides an important “proof of concept” for future studies aimed at characterizing signaling heterogeneity across primary leukemic...
cell samples. Moreover, these results corroborate genetic landscape data, suggesting that distinct signaling pathways are activated in subtypes of T-ALL [85].

Overall, the T-ALL cell populations we characterize in this study exhibit homogeneous phenotypes and monomodal distributions of the analyzed phosphoproteins. Therefore, herein we could not characterize heterogeneity at the single cell level within cell-line populations. However, phospho-specific flow cytometry is an especially useful tool for interrogating the physiology of signaling pathways by measuring network properties at the single-cell level, thus understanding the biology of heterogeneous populations of cells, such as those found in tumor samples from patients. Indeed, the signaling profile of any given leukemic cell is the sum of numerous influences—epigenetic, genetic and microenvironmental—and the heterogeneity of cancer cell behavior can be thought of reflecting the signaling differences that have arisen during the evolution of leukemic cell population. Therefore, integration of genomic and epigenetic studies with functional proteomic approaches at the single-cell level is fundamental to identify potential drug targets or biomarkers.

The functional flow cytometry approach we describe in this study provides a powerful tool for characterizing T-ALL heterogeneity across samples and has the potentiality to characterize signaling heterogeneity at the single level within primary leukemic cell populations. Therefore, it could represent an important tool for future studies on T-ALL primary cells aimed at identifying signaling elements as potential precision drug targets or biomarkers.

5. Conclusions

In this study, we demonstrated that phospho-specific flow cytometry can identify intrinsic and extrinsic signaling pathway activities and capture signaling network variability across different T-ALL cell lines. Overall, our study can contribute to a deeper understanding of the complex signaling network altered in T-ALL. Moreover, our data can form the basis for future studies on primary T-ALL cells connecting signaling properties with clinical behaviors and aimed at developing precision medicine tools, particularly for resistant and high-risk T-ALL patients.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11132072/s1, Table S1: Modulators used in the study, Table S2: Antibodies used for the detection of phosphoproteins, Table S3: Staining panels for the detection of phosphoproteins, Table S4: Antibodies used for the detection of cell surface protein expression, Figure S1: Comparison of expression of receptors for physiological stimuli, Figure S2: Unsupervised hierarchical clustering analysis of all the analyzed nodes, Figure S3: Unsupervised hierarchical clustering analysis on selected nodes.

Author Contributions: Conceptualization, methodology and formal analysis, O.P. and M.T.S.; investigation, O.P.; formal analysis, R.C., C.C. and M.G.; data curation, C.C. and M.G.; supervision, writing—original draft preparation and review, M.T.S.; funding acquisition, M.T.S. All authors have read and agreed to the published version of the manuscript.

Funding: Fondazione Cassa di Risparmio di Verona, Vicenza, Belluno e Ancona and Associazione Italiana Ricerca sul Cancro (AIRC), Italy (grant #6599 to M.T.S.).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki. The local Ethics Committee (Comitato Etico per la Sperimentazione Clinica, CESC, Verona, Italy) approved the anonymous use of leukocyte concentrate samples-as byproduct of the manufacturing of blood donation- for research purposes.

Informed Consent Statement: Written informed consent has been obtained from the blood donors for the collection and use of leukocyte concentrate samples-as byproduct of the manufacturing of their blood donation- for research purposes.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Girardi, T.; Vicente, C.; Cools, J.; De Keersmaecker, K. The Genetics and Molecular Biology of T-ALL. *Blood* 2017, 129, 1113–1123. [CrossRef] [PubMed]

2. Hunger, S.P.; Mullighan, C.G. Acute Lymphoblastic Leukemia in Children. *N. Engl. J. Med.* 2015, 373, 1541–1552. [CrossRef] [PubMed]

3. Litzow, M.R.; Ferrando, A.A. How I Treat T-Cell Acute Lymphoblastic Leukemia in Adults. *Blood* 2015, 126, 833–841. [CrossRef]

4. Pui, C.-H.; Robison, L.L.; Look, A.T. Acute Lymphoblastic Leukaemia. *Lancet* 2008, 371, 1030–1043. [CrossRef]

5. Aifantis, I.; Raetz, E.; Buonamici, S. Molecular Pathogenesis of T-Cell Leukaemia and Lymphoma. *Nat. Rev. Immunol.* 2008, 8, 380–390. [CrossRef]

6. Passaro, D.; Quang, C.T.; Ghysdael, J. Microenvironmental Cues for T-Cell Acute Lymphoblastic Leukemia Development. *Immunol. Rev.* 2016, 271, 156–172. [CrossRef]

7. Bene, M.C.; Castoldi, G.; Knapp, W.; Ludwing, W.D.; Matutes, E.; Orfao, A.; van’t Veer, M.B. Proposals for the Immunological Classification of Acute Leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). *Leukemia* 1995, 9, 1783–1786.

8. Raetz, E.A.; Teachey, D.T. T-Cell Acute Lymphoblastic Leukemia. *Hematol. Am. Soc. Hematol. Educ. Program.* 2016, 2016, 580–588. [CrossRef]

9. Jain, N.; Lamb, A.V.; O’Brien, S.; Ravandi, F.; Konopleva, M.; Jabbour, E.; Zuo, Z.; Jorgensen, J.; Lin, P.; Pierce, S.; et al. Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL/LBL) in Adolescents and Adults: A High-Risk Subtype. *Blood* 2016, 127, 1863–1869. [CrossRef]

10. Karpova, D.; Boing, H. Concise Review: CXCR4/CXCL12 Signaling in Immature Hematopoiesis—Lessons from Pharmacological Resistance. *Leukemia* 2021, 35, 3394–3405. [CrossRef] [PubMed]

11. Scupoli, M.T.; Perbellini, O.; Krampera, M.; Vinante, F.; Cioffi, F.; Pizzolo, G. IL-7 Requirement for Survival of T-Cell Acute Lymphoblastic Leukemia and Human Thymocytes on Bone Marrow Stroma. *Haematologica* 2007, 92, 264–266. [CrossRef] [PubMed]

12. Santagata, S.; Ieranò, C.; Trotta, A.M.; Capiluongo, A.; Guardascione, G.; Scala, S. CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment. *Front. Oncol.* 2021, 11, 1–11. [CrossRef] [PubMed]

13. Sanchez-Munoz, M.; Corcoran, A.E.; Ramírez, A.; Ramírez, M.; Toribio, M.I. IL-7R Is Essential for Leukemia-Initiating Cell Activity of T-Cell Acute Lymphoblastic Leukemia. *Blood* 2019, 134, 2171–2182. [CrossRef] [PubMed]

14. Scupoli, M.T.; Perbellini, O.; Palmieri, M.; et al. Bone Marrow Stromal Cells and the Upregulation of Interleukin-8 Production in Human T-Cell Acute Lymphoblastic Leukemia through the CXCL12/CXCR4 Axis and the NF-KB and JNK/AP-1 Pathways. *Haematologica* 2008, 93, 524–532. [CrossRef]

15. Santagata, S.; Ieranò, C.; Trotta, A.M.; Capiluongo, A.; Auletta, F.; Guardascione, G.; Scala, S. CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment. *Front. Oncol.* 2021, 11, 1–11. [CrossRef] [PubMed]

16. Chatterjee, S.; Behnam Azad, B.; Nimmagadda, S. The Intricate Role of CXCR4 in Cancer. *Adv. Cancer Res.* 2014, 124, 31–82. [PubMed]

17. Chatterjee, S.; Behnam Azad, B.; Nimmagadda, S. The Intricate Role of CXCR4 in Cancer. *Adv. Cancer Res.* 2014, 124, 31–82. [PubMed]

18. Teicher, B.A.; Fricker, S.P. CXCR12 (SDF-1)/CXCR4 Pathway in Cancer. *Clin. Cancer Res.* 2010, 16, 2927–2931. [CrossRef] [PubMed]

19. Scupoli, M.T.; Perbellini, O.; Krampera, M.; Vinante, F.; Cioffi, F.; Pizzolo, G. Interleukin 7 Requirement for Survival of T-Cell Acute Lymphoblastic Leukemia and Human Thymocytes on Bone Marrow Stroma. *Haematologica* 2007, 92, 264–266. [CrossRef] [PubMed]

20. Santagata, S.; Ieranò, C.; Trotta, A.M.; Capiluongo, A.; Guardascione, G.; Scala, S. CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment. *Front. Oncol.* 2021, 11, 1–11. [CrossRef] [PubMed]

21. Morrison, S.J.; Scadden, D.T. The Bone Marrow Niche for Haematopoietic Stem Cells. *Nature* 2014, 505, 327–334. [CrossRef] [PubMed]

22. Singh, A.K.; Arya, R.K.; Trivedi, A.K.; Sanyal, S.; Baral, R.; Dormond, O.; Briscoe, D.M.; Datta, D. Chemokine Receptor Trios: CXCR3, CXCR4 and CXCR7 Crosstalk via CXCL11 and CXCL12. *Cytokine Growth Factor Rev.* 2013, 24, 41–49. [CrossRef] [PubMed]

23. Bianchi, M.E.; Mezzapelle, R. The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration. *Front. Immunol.* 2020, 11, 1–8. [CrossRef] [PubMed]

24. Rombouts, E.J.C.; Pavic, B.; Löwenberg, B.; Ploemacher, R.E. Relation between CXCR-4 Expression, Flt3 Mutations, and Unfavorable Prognosis of Adult Acute Myeloid Leukemia. *Blood* 2004, 104, 550–557. [CrossRef] [PubMed]
Cells 2022, 11, 2072

27. Patel, B.; Dey, A.; Castleton, A.Z.; Schwab, C.; Samuel, E.; Sivakumaran, J.; Beaton, B.; Zareian, N.; Zhang, C.Y.; Rai, L.; et al. Mouse Xenograft Modeling of Human Adult Acute Lymphoblastic Leukemia Provides Mechanistic Insights into Adult LIC Biology. *Blood* 2014, 124, 96–105. [CrossRef]

28. Pitt, L.A.; Tikhonova, A.N.; Hu, H.; Trimarchi, T.; King, B.; Gong, Y.; Sanchez-Martin, M.; Tsirigos, A.; Littman, D.R.; Ferrando, A.A.; et al. CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. *Cancer Cell* 2015, 27, 755–768. [CrossRef]

29. Passaro, D.; Irigoyen, M.; Catherinet, C.; Gachet, S.; Da Costa De Jesus, C.; Lasgi, C.; Tran Quang, C.; Ghysdael, J. CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia. *Cancer Cell* 2015, 27, 769–779. [CrossRef]

30. Melo, R.D.C.C.; Longhini, A.L.; Bibarella, C.L.; Baratti, M.O.; Traina, F.; Favaro, P.; Campos, P.D.M.; Saad, S.T.O. CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12. *PLoS ONE* 2014, 9, e91365. [CrossRef]

31. Barata, J.T.; Durum, S.K.; Seddon, B. Flip the Coin: IL-7 and IL-7R in Health and Disease. *Nat. Immunol.* 2019, 20, 1584–1593. [CrossRef] [PubMed]

32. Oliveira, M.L.; Akkapeddi, P.; Ribeiro, D.; Melão, A.; Barata, J.T. IL-7R-Mediated Signaling in T-Cell Acute Lymphoblastic Leukemia: An Update. *Adv. Biol. Regul.* 2019, 71, 88–96. [CrossRef] [PubMed]

33. Barata, J.T.; Cardoso, A.A.; Boussiotis, V.A. Interleukin-7 Promotes Survival and Cell Cycle Progression of T-Cell Acute Lymphoblastic Leukemia Cells: An Extrinsic Factor Supporting Leukemogenesis? *Leuk. Lymphoma* 2005, 46, 483–495. [CrossRef] [PubMed]

34. Jiang, Q.; Wen, Q.L.; Aiello, F.B.; Mazzucchelli, R.; Asfia, B.; Khaled, A.R.; Durum, S.K. Cell Biology of IL-7, a Key Lymphotrophin. *Cytokine Growth Factor Rev.* 2005, 16, 513–533. [CrossRef] [PubMed]

35. Barata, J.T.; Cardoso, A.A.; Nadler, L.M.; Boussiotis, V.A. Interleukin-7 Promotes Survival and Cell Cycle Progression of T-Cell Acute Lymphoblastic Leukemia Cells by Down-Regulating the Cyclin-Dependent Kinase Inhibitor P27kip1. *Blood* 2001, 98, 1524–1531. [CrossRef]

36. Silva, A.; Girio, A.; Cebola, I.; Santos, C.I.; Antunes, F.; Barata, J.T. Intracellular Reactive Oxygen Species Are Essential for PE3B/Akt/MTOR-Dependent IL-7R-Mediated Viability of T-Cell Acute Lymphoblastic Leukemia Cells. *Leukemia* 2011, 25, 960–967. [CrossRef]

37. Swainson, L.; Kinet, S.; Mongellaz, C.; Sourisseau, M.; Henriques, T.; Taylor, N. IL-7-Induced Proliferation of Recent Thymic Emigrants Requires Activation of the PI3K Pathway. *Blood* 2007, 109, 1034–1042. [CrossRef]

38. Rathmell, J.C.; Farkash, E.A.; Gao, W.; Thompson, C.B. IL-7 Enhances the Survival and Maintains the Size of Naive T Cells. *J. Immunol.* 2001, 167, 6869–6876. [CrossRef]

39. Irish, J.M.; Kotecha, N.; Nolan, G.P. Mapping Normal and Cancer Cell Signalling Networks: Towards Single-Cell Proteomics. *Adv. Biol. Regul.* 2020, 6, 141–146. [CrossRef]

40. Cesano, A.; Perbellini, O.; Evesen, E.; Chu, C.C.; Cioffi, F.; Ptacek, J.; Damle, R.N.; Chignola, R.; Cordeiro, J.; Yan, X.J.; et al. Association between B-Cell Receptor Responsiveness and Disease Progression in B-Cell Chronic Lymphocytic Leukemia: Results from Single Cell Network Profiling Studies. *Haematologica* 2013, 98, 626–634. [CrossRef]

41. Cavallini, C.; Chignola, R.; Dando, I.; Perbellini, O.; Mimiola, E.; Lovato, O.; Laudanna, C.; Pizzolo, G.; Donadelli, M.; Scupoli, M.T. Low Catalase Expression Confers Redox Hypersensitivity and Identifies an Indolent Clinical Behavior in CLL. *Blood* 2015, 126, 333–342. [CrossRef] [PubMed]

42. Cavallini, C.; Galasso, M.; Pozza, E.D.; Chignola, R.; Lovato, O.; Dando, I.; Romanelli, M.G.; Krampfera, M.; Pizzolo, G.; Donadelli, M.; et al. Effects of CD20 Antibodies and Kinase Inhibitors on B-Cell Receptor Signalling and Survival of Chronic Lymphocytic Leukaemia Cells. *Br. J. Haematol.* 2021, 192, 158–167. [CrossRef] [PubMed]

43. Scupoli, M.T.; Vinante, F.; Krampfera, M.; Vincenzi, C.; Nadali, G.; Zampieri, F.; Ritter, M.A.; Eren, E.; Santini, F.; Pizzolo, G. Thymic Epithelial Cells Promote Survival of Human T-Cell Acute Lymphoblastic Leukemia Blasts: The Role of Interleukin-7. *Haematologica* 2003, 88, 1229–1237. [PubMed]

44. Metsalu, T.; Vilo, J. ClustVis: A Web Tool for Visualizing Clustering of Multivariate Data Using Principal Component Analysis and Heatmap. *Nucleic Acids Res.* 2015, 43, W566–W570. [CrossRef] [PubMed]

45. Singh, D.K.; Kumar, D.; Siddiqui, Z.; Basu, S.K.; Kumar, V.; Rao, K.V.S. The Strength of Receptor Signaling Is Centrally Controlled through a Cooperative Loop between Ca2+ and an Oxidant Signal. *Cell* 2005, 121, 281–293. [CrossRef]

46. Dröge, W. Protein Kinase C in T-Cell Regulation. *Immunol. Today* 1986, 7, 340–343. [CrossRef]

47. Kornblau, S.M.; Minden, M.D.; Rosen, D.B.; Putta, S.; Cohen, A.; Covey, T.; Spellmeyer, D.C.; Fantl, W.J.; Gayko, U.; Cesano, A. Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy. *Clin. Cancer Res.* 2010, 16, 3721–3733. [CrossRef]

48. Irish, J.M.; Hovland, R.; Krutzik, P.O.; Perez, O.D.; Bruserud, Ø.; Gjertsen, B.T.; Nolan, G.P. Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells. *Cell* 2004, 118, 217–228. [CrossRef]

49. Irish, J.M.; Czerwinski, D.K.; Nolan, G.P.; Levy, R. Kinetics of B Cell Receptor Signaling in Human B Cell Subsets Mapped by Phosphospecific Flow Cytometry. *J. Immunol.* 2006, 177, 1581–1589. [CrossRef]

50. Štefanová, I.; Hemmer, B.; Vergelli, M.; Martin, R.; Biddison, W.E.; Germain, R.N. TCR Ligand Discrimination Is Enforced by Competing ERK Positive and SHP-I Negative Feedback Pathways. *Nat. Immunol.* 2003, 4, 248–254. [CrossRef]

51. Alberolalla, J.; Forbes, K.; Seger, R.; Krebs, E.G.; Perlmutter, R.M. Selective Requirement for MAP Kinase Activation in Thymocyte Differentiation. *Nature* 1995, 373, 620–623. [CrossRef] [PubMed]
76. Barata, J.T.; Silva, A.; Brandao, J.G.; Nadler, L.M.; Cardoso, A.A.; Boussiotis, V.A. Activation of PI3K Is Indispensable for Interleukin 7-Mediated Viability, Proliferation, Glucose Use, and Growth of T Cell Acute Lymphoblastic Leukemia Cells. J. Exp. Med. 2004, 200, 659–669. [CrossRef]

77. Lonetti, A.; Antunes, I.L.; Chiarini, F.; Orsini, E.; Buontempo, F.; Ricci, F.; Tazzari, P.L.; Pagliaro, P.; Melchionda, F.; Pession, A.; et al. Activity of the Pan-Class I Phosphoinositide 3-Kinase Inhibitor NVP-BKM120 in T-Cell Acute Lymphoblastic Leukemia. Leukemia 2014, 28, 1196–1206. [CrossRef]

78. Zhao, W.-L. Targeted Therapy in T-Cell Malignancies: Dysregulation of the Cellular Signaling Pathways. Leukemia 2010, 24, 13–21. [CrossRef]

79. Evangelisti, C.; Ricci, F.; Tazzari, P.; Chiarini, F.; Battistelli, M.; Falcieri, E.; Ognibene, A.; Pagliaro, P.; Cocco, L.; McCubrey, J.A.; et al. Preclinical Testing of the Akt Inhibitor Triciribine in T-Cell Acute Lymphoblastic Leukemia. J. Cell. Physiol. 2011, 226, 822–831. [CrossRef]

80. Hess, P.; Pihan, G.; Sawyers, C.L.; Flavell, R.A.; Davis, R.J. Survival Signaling Mediated by C-Jun NH2-Terminal Kinase in Transformed B Lymphoblasts. Nat. Genet. 2002, 32, 201–205. [CrossRef]

81. Gururajan, M.; Chui, R.; Karuppannan, A.K.; Ke, J.; Jennings, C.D.; Bondada, S. C-Jun N-Terminal Kinase (JNK) Is Required for Survival and Proliferation of B-Lymphoma Cells. Blood 2005, 106, 1382–1391. [CrossRef]

82. Hideshima, T.; Hayashi, T.; Chauhan, D.; Akiyama, M.; Richardson, P.; Anderson, K. Biologic Sequelae of C-Jun NH2-Terminal Kinase (JNK) Activation in Multiple Myeloma Cell Lines. Oncogene 2003, 22, 8797–8801. [CrossRef] [PubMed]

83. Cui, J.; Wang, Q.; Wang, J.; Lv, M.; Zhu, N.; Li, Y.; Feng, J.; Shen, B.; Zhang, J. Basal C-Jun NH2-Terminal Protein Kinase Activity Is Essential for Survival and Proliferation of T-Cell Acute Lymphoblastic Leukemia Cells. Mol. Cancer Ther. 2009, 8, 3214–3222. [CrossRef] [PubMed]

84. Chen, T.J.; Du, W.; Junco, J.J.; Bridges, C.S.; Shen, Y.; Puppi, M.; Rabin, K.R.; Lacorazza, H.D. Inhibition of the MAP2K7-JNK Pathway with 5Z-7-Oxozeaenol Induces Apoptosis in T-Cell Acute Lymphoblastic Leukemia. Oncotarget 2021, 12, 1787–1801. [CrossRef] [PubMed]

85. Liu, Y.; Easton, J.; Shao, Y.; Maciaszek, J.; Wang, Z.; Wilkinson, M.R.; McCastlain, K.; Edmonson, M.; Pounds, S.B.; Shi, L.; et al. The Genomic Landscape of Pediatric and Young Adult T-Lineage Acute Lymphoblastic Leukemia. Nat. Genet. 2017, 49, 1211–1218. [CrossRef] [PubMed]